Regional differences in access to direct-acting antiviral treatments for hepatitis C across Ontario

An estimated 71 million people worldwide live with chronic hepatitis C virus (HCV) infection which, if left untreated, can increase morbidity and mortality. Direct-acting antivirals (DAAs) are curative treatments for HCV. However, initiation of these treatments depends on access to health care and physicians that can diagnose and initiate treatment.

The aim of this study is to understand the relationship between DAA treatment rates and distance to prescriber in Ontario, Canada.

The following maps examine trends in HCV DAA medication prescribing and the average distance to a prescriber by public health unit in Ontario in 2019.

Please note that this report is NOT COMPLETE and is still in progress. Click below if you would like to continue.